UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2008
------------------------------------------------------

Commission file number 000-15303
---------------------------------------------------------

HST GLOBAL, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)

Nevada 73-1215433
- --------------------------------------------------------------------------------
(State or other jurisdiction of (I. R.S. Employer Identification No.)
incorporation or organization)

150 Research Drive, Hampton, VA 23666
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)

Issuer's telephone number 757-766-6100
--------------

Copy to:

Cutler Law Group
3206 W. Wimbledon Dr.
Augusta, GA 30909
Fax: 800-836-0714

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Name of Each Exchange on which Registered

None None
- --------------------------------------------------------------------------------

Securities registered pursuant to Section 12(g) of the Act:

Common Stock ($0.001 par value)
- --------------------------------------------------------------------------------
(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act. [ ] Yes [x] No

Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. [ ] Yes [x] No

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [x] Yes [ ] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K ( 229.405 of this chapter) is not contained herein, and will
not be contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-K
or any amendment to this Form 10-K. [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting company. See
definition of "accelerated filer, large accelerated filer and smaller reporting
company" as defined in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ]
Non-accelerated filer [ ] Smaller reporting company [X]
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Act). [ ] Yes [x] No

The aggregate market value of the common equity held by non-affiliates of the
registrant as of June 30, 2008 (the last business day of the registrant's most
recently completed second fiscal quarter) was $14,903,530. This number reflects
the reverse split effected July 7, 2008.

The number of shares of the registrant's common stock outstanding as of March
25, 2009 was 24,966,053 shares.

HST GLOBAL, INC.
TABLE OF CONTENTS

PART I

Forward Looking Statements.....................................................4
Item 1. Business..........................................................4
Item 1A. Risk Factors......................................................8
Item 1B. Unresolved Staff Comments.........................................8
Item 2. Properties........................................................8
Item 3. Legal Proceedings.................................................9
Item 4. Submission of Matters to a Vote of Security Holders...............9

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities.................9
Item 6. Selected Financial Data..........................................11
Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operations........................................11
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.......13
Item 8. Financial Statements and Supplementary Data......................13
Item 9. Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure.........................................23
Item 9A. Controls and Procedures..........................................23
Item 9B. Other Information................................................24

PART III

Item 10. Directors and Executive Officers of the Registrant...............24
Item 11. Executive Compensation...........................................26
Item 12. Security Ownership of Certain Beneficial Owners and Management...30
Item 13. Certain Relationships and Related Transactions...................31
Item 14. Principal Accounting Fees and Services...........................32

PART IV

Item 15. Exhibits and Financial Statement Schedules.......................33
Signatures....................................................................34

Page 3

FORWARD-LOOKING STATEMENTS

In addition to historical information, this Report contains forward-looking
statements. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
reflected in these forward-looking statements. Factors that might cause such a
difference include, but are not limited to, management of growth, competition,
pricing pressures on the Company's products, industry growth and general
economic conditions. Readers are cautioned not to place undue reliance on these
forward-looking statements, which reflect management's opinions only as of the
date hereof. The Company undertakes no obligation to revise or publicly release
the results of any revision to these forward-looking statements.

PART I

ITEM 1. BUSINESS

A. BUSINESS DEVELOPMENT

There have been no changes to our business development during the year ended
December 31, 2008.

B. FINANCIAL INFORMATION ABOUT SEGMENTS

As defined by generally accepted accounting principles ("GAAP"), we do not have
any segments separate and apart from our business as a whole. Accordingly,
there are no measures of revenue from external customers, profit and loss, or
total assets aside from what is reported in the Financial Statements attached to
this Form 10-K.

C. BUSINESS OF THE COMPANY

COMPANY OVERVIEW

HST Global, Inc. is an Integrated Health and Wellness company that is developing
and / or acquiring a network of Wellness Centers worldwide that are primarily
focused on the homeopathic and alternative treatment of late stage cancer. In
addition, the company intends to acquire innovative products for the treatment
of late stage cancer. In this regard, the company primarily focuses on
homeopathic and alternative product candidates that are undergoing or have
already completed significant clinical testing for the treatment of late stage
cancer.

The company has identified the growing acceptance of alternative cancer
treatments worldwide which has placed us in a perfect position to open our own
brand of Cancer Treatment Centers. This strategy will enable the company to
address the challenges individuals face in the treatment of cancer in the later
stages.

We intend to open our first Cancer Institute during the second quarter of 2009.
The company also intends to open a total of three (3) to five (5) Cancer Centers
during 2009.

Our executive offices are located at 150 Research Drive Hampton, VA 23666. Our
telephone number is 757-766-6100 and our internet address is www.hstglobal.com.
-----------------

Page 4

BUSINESS MODEL AND STRATEGY

Cancer is an epidemic that is worldwide and one that does not discriminate. The
company has been involved with pre-clinical and proven product candidates that
have shown high efficacy in the treatment of various late stage cancers. The
success and high efficacy achieved in these treatments has given the company a
position of visibility that has attracted a number of International partners
that want to move forward and open Centers worldwide. Movement to establish a
global chain of Cancer Treatment Centers will provide an immediate revenue
stream to the company.

Due to the change in the perception of homeopathic treatments for cancer and
other life threatening illnesses, the company has developed a strategy of
opening a chain of Wellness Centers worldwide. The clinics will be called FIT
Wellness Centers. It is the company's intention to open its first clinic during
the second quarter of 2009. In addition, the company intends to open a total of
three (3) to five (5) partner centers worldwide during fiscal 2009. After an
initial one year ramp-up period, anticipated annual gross revenues for each
individual clinic should be approximately between 8 and 10 million dollars per
year.

As referenced above, the company also focuses on alternative and homeopathic
products that are undergoing or have already completed significant clinical
testing for the treatment of late stage cancer. Currently, we do not follow any
policy or formula as to our acquisition of product candidates, other than
seeking products for which pre-clinical or clinical testing has commenced.

REPORT BY THE SCIENTIFIC ADVISORY BOARD

The following summarizes the findings of our Scientific Advisory Board with
respect to the ongoing clinical trials:

The purpose of the pre-clinical outcome-based study in Stage IV adult cancers is
to study efficacy and safety issues. All patients coming to the clinic are
given the following choices:

1. Conventional chemotherapy, either first, second or third line, as
appropriate to the patient's prior history;
2. Conventional chemotherapy, either standard or low-dose
fractionated, with "Forsythe Immune Therapy" ("FIT");
3. Conventional dose or low-dose fractionated chemotherapy with
"FIT" and other complimentary products;
4. "FIT" along with other complimentary therapies;
5. "FIT" alone;
6. Insulin potentiated therapy using standard chemotherapy with "FIT";
and
7. Any of the above plus hormonal therapies.

This study was carried out from June of 2005 through March of 2008, with 250
Stage IV cancer patients under study.

The advantages of the pre-clinical study were to show efficacy and safety, and
freedom from adverse toxicities and adverse side-effects. The conclusion of the
study was that "FIT" is a novel, homeopathic, immune boosting therapy that when
used alone in breast cancer, isolated from the other cancers, showed an overall
response rate of 78% at 33 months.

It is important to note that "FIT" is compatible with other complimentary
therapies, which vector in on the metabolism of the cancer cell in a different
matter.

Page 5

In the entire study there were 13% complete remissions, 16% partial remissions,
and 41% stable diseases, with an overall 30% expiration rate.

These results compared favorably with conventional chemotherapy alone which, in
five years in the allopathic literature from 2004, showed only a 2.1% survival
rate in the United States with any form of chemotherapy alone.

Also of great importance is the fact that there were no significant adverse
events in the 250 patients using "FIT", even when used with low-dose
fractionated chemotherapy.

RESULTS OF CLINICAL TRIALS

The following summarizes the results of the ongoing clinical trials:

Total number of breast cancer patients = 58.
Total number of expirations = 12 or 21%.
Total surviving = 46 or 79%.

Total number receiving "FIT" only = 9.
Total number of expirations = 1 or 11%.
Total surviving = 8 or 89%.

Total number receiving "FIT"plus Complementary = 22.
Total number of expirations = 5 or 23%.
Total surviving = 17 or 77%.

Total number receiving "FIT", Complementary plus Chemotherapy = 20.
Total number of expirations = 5 or 25%.
Total surviving = 15 or 75%.

Total receiving Low-dose Conventional Chemotherapy plus Glyco"FIT" = 7.
Total expirations = 1 or 14%.
Total surviving = 6 or 86%

As noted above, the advantages of the pre-clinical study were to show efficacy
and safety, and freedom from adverse toxicities and adverse side-effects. The
conclusion of the study was that "FIT" is a novel, homeopathic, immune boosting
therapy that when used alone in breast cancer, isolated from the other cancers,
showed high efficacy.

ABOUT BREAST CANCER

According to The American Cancer Society, breast cancer is the most common
cancer among women in the United States, other than skin cancer. It is the
second leading cause of cancer death in women, after lung cancer.

About 178,480 women in the United States will be found to have invasive breast
cancer in 2007. About 40,460 women will die from the disease this year. Right
now there are about two and a half million breast cancer survivors in the United
States. The chance of a woman having invasive breast cancer some time during
her life is about 1 in 8. The chance of dying from breast cancer is about 1 in
35. Breast cancer death rates are going down. This is probably the result of
finding the cancer earlier and improved treatment.

Page 6

TYPES OF BREAST CANCERS

There are many types of breast cancer, though some of them are very rare.
Sometimes a breast tumor can be a combination of these types and have a mixture
of "invasive" and "in situ" cancer.

Ductal carcinoma in situ (DCIS): This is the most common type of non-invasive
breast cancer. DCIS means that the cancer is only in the ducts. It has not
spread through the walls of the ducts into the tissue of the breast. Nearly all
women with cancer at this stage can be cured. Often the best way to find DCIS
early is with a mammogram.

Lobular carcinoma in situ (LCIS): This condition begins in the milk-making
glands but does not go through the wall of the lobules. Although not a true
cancer, having LCIS increases a woman's risk of getting cancer later. For this
reason, it's important that women with LCIS follow the screening guidelines for
breast cancer (these are discussed later in this document).

Invasive (infiltrating) ductal carcinoma (IDC): This is the most common type of
breast cancer. It starts in a milk passage or duct, breaks through the wall of
the duct, and invades the tissue of the breast. From there it can spread to
other parts of the body. It accounts for about 8 out of 10 invasive breast
cancers.

Invasive (infiltrating) lobular carcinoma (ILC): This cancer starts in the milk
glands or lobules. It can spread to other parts of the body. About 1 out of 10
invasive breast cancers are of this type.

Inflammatory breast cancer (IBC): This uncommon type of invasive breast cancer
accounts for about 1% to 3% of all breast cancers. Usually there is no single
lump or tumor. Instead, inflammatory breast cancer (IBC) makes the skin of the
breast look red and feels warm. It also gives the skin a thick, pitted
appearance that looks a lot like an orange peel. Doctors now know that these
changes are not caused by inflammation or infection, but by cancer cells
blocking lymph vessels in the skin. The breast may become larger, firmer,
tender, or itchy. IBC is often mistaken for an infection in its early stages.
Because there is no defined lump, it may not appear on a mammogram, which may
make it even harder to catch it early. It usually has a higher chance of
spreading and a worse outlook than invasive ductal or lobular cancer.

OTHER MATTERS

Employees
- ---------

HST Global, Inc. and Health Source Technologies, Inc., our wholly owned
subsidiary, have a total of six full time employees and two consultants who
devote a significant portion of their time to the Company. We believe our
relationship with our employees is good.

Consulting Agreement
- --------------------

We have engaged Eric Clemons as a consultant to the Company. Pursuant to the
consulting agreement, the Company will pay Mr. Clemons $10,000 per month thru
December 31, 2008. The agreement can be terminated by the Company at will. We
intend to retain Mr. Clemons as a consultant until his services are no longer
required by the Company.

Page 7

Research and Development
- ------------------------

During the last two full fiscal years, we have not engaged in any research and
development activities. Our business model is to in-license technologies
developed by others. In the event that we undertake research and development
activities in the future, the costs of those efforts will not be bourn directly
by our consumers.

Intellectual Property
- ---------------------

Our goal is to obtain, maintain and enforce patent protection for our products,
formulations, processes, methods and other proprietary technologies, preserve
our trade secrets, and operate without infringing on the proprietary rights of
other parties, both in the United States and in other countries. Our policy is
to actively seek to obtain, where appropriate, the broadest intellectual
property protection possible for any future product candidates, proprietary
information and proprietary technology through a combination of contractual
arrangements and patents, both in the U.S. and abroad.

Dependence on one or a few major customers
- ------------------------------------------

HSTC is not dependent on one or a few major customers.

Competition
- -----------

The treatment of late stage cancer is highly competitive, and there will be
considerable competition from major pharmaceutical, biotechnology, and specialty
cancer companies. Many of our competitors have substantially more resources
than we do, including both financial and technical resources. In addition, many
of these companies have more experience than we do in preclinical and clinical
development, manufacturing, regulatory, and global commercialization. We are
also competing with academic institutions, governmental agencies and private
organizations that are conducting research in the field of cancer. Competition
for highly qualified employees is intense.

ITEM 1A. RISK FACTORS

Not required by smaller reporting companies.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

The Company's executive offices are located at 150 Research Dr., Hampton VA. We
currently share these offices with The Health Network, Inc. ("THN"), of which
Ron Howell is President. We have no formal sublease or rental agreement with
THN; however, we currently pay to THN $15,000 per month as an operating fee,
which includes use of the office space among other things. The combined office
and warehouse space is 42,600 square feet.

Page 8

ITEM 3. LEGAL PROCEEDINGS

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES

MARKET INFORMATION

Our common stock is quoted in United States markets on the Over-The-Counter
Bulletin Boards ("OTC BB"), under the symbol "HSTC.OB." There is no assurance
that the common stock will continue to be traded on the OTC BB or that any
liquidity exists for our shareholders.

MARKET PRICE

The following table shows the high and low per share price quotations of the
Company's common stock as reported by the OTC BB for the periods presented.
These quotations reflect inter-dealer prices, without retail mark-up, mark-down
or commissions, and may not necessarily represent actual transactions. The OTC
BB market is extremely limited and the prices quoted by brokers are not a
reliable indication of the value of the common stock. The periods presented
represent fiscal quarters, with the fourth quarter of each year ending on
December 31.

HIGH LOW
Fiscal 2006
First Quarter* 1.20 0.22
Second Quarter* 2.10 1.05
Third Quarter* 2.42 0.45
Fourth Quarter* 0.74 0.19

Fiscal 2007
First Quarter* 0.30 0.13
Second Quarter* 0.20 0.07
Third Quarter* 0.15 0.04
Fourth Quarter* 0.07 0.03

Fiscal 2008
First Quarter* 0.07 0.03
Second Quarter* 0.91 0.05
Third Quarter (through July 6)* 0.35 0.15
Third Quarter (July 7 to September 30) 10.50 2.50
Fourth Quarter 5.90 2.20

* Numbers do not reflect the 1 for 25 reverse split effective July 7, 2008.

Page 9

As of December 31, 2008, the Company had 100,000,000 shares of common stock
authorized with 24,886,053, issued and outstanding. The Company had 5,000,000
shares of preferred stock authorized with no shares issued and outstanding.

PENNY STOCK REGULATIONS

Our common stock is quoted in United States markets on the OTC BB under the
symbol "HSTC.OB." Since the July 7, 2008 reverse split, the sale price of our
common stock, thru December 31, 2008, has been reported as low as $2.20 per
share. As such, the Company's common stock may be subject to provisions of
Section 15(g) and Rule 15g-9 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), commonly referred to as the "penny stock rule."

Section 15(g) sets forth certain requirements for transactions in penny stocks,
and Rule 15g-9(d) incorporates the definition of "penny stock" that is found in
Rule 3a51-1 of the Exchange Act. The SEC generally defines "penny stock" to be
any equity security that has a market price less than $5.00 per share, subject
to certain exceptions. As long as the Company's common stock is deemed to be a
penny stock, trading in the shares will be subject to additional sales practice
requirements on broker-dealers who sell penny stocks to persons other than
established customers and accredited investors.

DIVIDENDS

The Company has not issued any dividends on the common stock to date, and does
not intend to issue any dividends on the common stock in the near future. We
currently intend to use all profits to further the growth and development of the
Company.

NUMBER OF SHARES OUTSTANDING

As of December 31, 2008, the Company had 100,000,000 shares of common stock
authorized with 24,886,053 issued and outstanding and 1,421,914 freely tradable
shares in the public float. These shares were held by approximately 622
shareholders of record. The Company had 5,000,000 shares of preferred stock
authorized with no shares issued and outstanding.

RECENT SALES OF UNREGISTERED SECURITIES

The following represent all sales of unregistered securities during fiscal 2008
and the subsequent interim period up to the date hereof:

On March 16, 2009, the company received $25,000 from an investor for working
capital. This investor was issued 20,000 shares, at a price of $1.25 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On February 20, 2009, the company received $75,000 from an investor for working
capital. This investor was issued 60,000 shares, at a price of $1.25 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On December 31, 2008, the Company issued 1,994,896 shares of common stock to
Ronald Howell as part of the consideration for the Acquisition of Health Source
Technologies, Inc. This issuance was completed in accordance with Section 4(2)
of the Securities Act in an offering without any public offering or
distribution. These shares are restricted securities and include an appropriate
restrictive legend.

Page 10

On December 31, 2008, the Company issued 1,994,896 shares of common stock to
Eric Clemons as part of the consideration for the Acquisition of Health Source
Technologies, Inc. This issuance was completed in accordance with Section 4(2)
of the Securities Act in an offering without any public offering or
distribution. These shares are restricted securities and include an appropriate
restrictive legend.

On October 28, 2008, the company received $250,000 from an investor for working
capital. This investor will receive 125,000 shares, at a price of $1.25 per
share.

On August 20, 2008, the Company issued 839,200 shares to 22 investors as
subscriptions to a private offering, at a price of $1.25 per share. This
issuance was completed in accordance with Section 4(2) of the Securities Act in
an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On August 20, 2008, the Company issued 15,000 shares for legal services. This
issuance was completed in accordance with Section 4(2) of the Securities Act in
an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On May 9, 2008, the Company issued 4,200,000 shares on the conversion of certain
debt. This issuance was completed in accordance with Section 4(2) of the
Securities Act in an offering without any public offering or distribution.
These shares are restricted securities and include an appropriate restrictive
legend.

On May 9, 2008, the Company issued 66,000,000 shares of common stock to Health
Source Technologies, Inc. as part of the consideration for the Acquisition of
Health Source Technologies, Inc. This issuance was completed in accordance with
Section 4(2) of the Securities Act in an offering without any public offering or
distribution. These shares are restricted securities and include an appropriate
restrictive legend.

On May 7, 2008, the Company issued 1,000,000 shares of Series A Preferred Stock
to Health Source Technologies, Inc. as part of the consideration for the
Acquisition of Health Source Technologies, Inc. Following the effective date of
the one for twenty five reverse split, all of these shares were converted into
16,200,000 shares of common stock. This issuance was completed in accordance
with Section 4(2) of the Securities Act in an offering without any public
offering or distribution. These shares are restricted securities and include an
appropriate restrictive legend.

PURCHASES OF EQUITY SECURITIES

None.

ITEM 6. SELECTED FINANCIAL DATA

Not required by smaller reporting companies.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATION

FORWARD-LOOKING STATEMENTS

Statements about our future expectations are "forward-looking statements" within
the meaning of applicable Federal Securities Laws, and are not guarantees of
future performance. When used herein, the

Page 11

words "may," "will," "should," "anticipate," "believe," "appear," "intend,"
"plan," "expect," "estimate," "approximate," and similar expressions are
intended to identify such forward-looking statements. These statements involve
risks and uncertainties inherent in our business, including those set forth in
Item 1A under the caption "Risk Factors," in this Annual Report on Form 10-K for
the year ended December 31, 2008, and other filings with the SEC, and are
subject to change at any time. Our actual results could differ materially from
these forward-looking statements. We undertake no obligation to update publicly
any forward-looking statement.

OVERVIEW

HST Global, Inc. (the "Company") is a Hampton, Virginia based company that is
developing and acquiring a network of Wellness Centers worldwide that are
primarily focused on the homeopathic and alternative treatment of late stage
cancer. In addition, the company intends to acquire innovative products for the
treatment of late stage cancer. In this regard, the company primarily focuses on
homeopathic and alternative product candidates that are undergoing or have
already completed significant clinical testing for the treatment of late stage
cancer.

The company has identified a growing acceptance of alternative cancer treatments
worldwide which has placed us in a perfect position to open our own brand of
Cancer Treatment Centers. While we continue to look for homeopathic and
alternative product candidates, this strategy will enable the company to address
the challenges individuals face in the treatment of cancer in the later stages.

PLAN OF OPERATION

We intend to open our first Cancer Institute during the second quarter of 2009.
The company also intends to open three (3) to five (5) Cancer Centers during
2009.

Our plan of operation for the next 12 months is to continue implementing our
business strategy of developing and/or acquiring three (3) to five (5) "FIT"
Wellness Centers throughout the world and the acquisition of innovative
homeopathic and alternative late stage cancer products.

We expect our principal expenditures during this period to include:

- operating expenses, including expanded research and development
and general and administrative expenses; and

- the opening of three (3) to five (5) "FIT" Wellness Centers over
the next year.

General and administrative expenses consist primarily of salaries and related
personnel costs, professional fees, business insurance, rent, general legal
activities, and other corporate expenses.

We have never been profitable and do not anticipate having net income unless and
until we develop and/or acquire our wellness centers. With respect to our
current activities, this is not likely to occur until we obtain significant
additional funding. We cannot provide any assurance that we will be able to
achieve profitability on a sustained basis, if at all, obtain the required
funding, obtain, or complete additional corporate partnering or acquisition
transactions.

Accordingly, we will need to raise additional funds or pursue strategic
transactions or other strategic alternatives. To date, we have financed our
operations primarily through private sales of our equity securities, and we
expect to continue obtaining required capital in a similar manner.

Page 12

RESULTS OF OPERATIONS

Revenues, cost of sales and operating expenses
- ----------------------------------------------

The Company had revenues of $0 for the year ended December 2008 as compared to
$0 for the year ended December 2007. The costs of sales for the same period
were $0 in 2008 as compared to $0 for 2007. The Company incurred expenses of
$1,513,333 for the year ended December 2008. The expenses in the year 2008 were
incurred to reorganize the Company. Until the Company obtains capital required
to develop any properties or businesses and obtains the revenues needed from its
future operations to meet its obligations, the Company will be dependent upon
sources other than operating revenues to meet its operating and capital needs.
Operating revenues may never satisfy these needs.

Gain on discontinued operations
- -------------------------------

No income or loss was recorded in the current quarter from discontinued
operations or from the disposal of a subsidiary.

LIQUIDITY AND CAPITAL RESOURCES

Our capital requirements arise principally due to our expenses in beginning our
operations and our plan to open up to five Wellness Centers in 2009. Our cash
balance as of December 31, 2008 was $776.

The Company does not currently have sufficient capital in its accounts, nor
sufficient firm commitments for capital to assure its ability to meet its
current obligations or to continue its planned operations. The Company is
continuing to pursue working capital and additional revenue through the seeking
of the capital it needs to carry on its planned operations. There is no
assurance that any of the planned activities will be successful.

OFF-BALANCE SHEET ARRANGEMENTS

None.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

None.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Description Page
- ----------- ----

Report of Independent Registered Public Accounting Firm F-14

Consolidated Balance Sheets F-15

Consolidated Statements of Operations F-16

Consolidated Statements of Changes in Shareholders' Interest F-17

Consolidated Statements of Cash Flows F-18

Notes to Consolidated Financial Statements F-19

Page 13

Board of Directors
HST Global, Inc. and Subsidiary
Hampton, Virginia

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have audited the accompanying consolidated balance sheet of HST Global, Inc.
and Subsidiary (Formerly NT Holding Corp.) (A Development Stage Company) as of
December 31, 2008 and the consolidated statements of operations, stockholders'
equity(deficiency) and cash flows for the year ended December 31, 2008, and for
the period from inception on August 6, 2007 to December 31, 2007 and 2008.
These consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audit.

We conducted our audit in accordance with auditing standards of the Public
Company Accounting Oversight Board ("PCAOB"). Those standards require that we
plan and perform an audit to obtain reasonable assurance whether the financial
statements are free of material misstatement. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over
financial reporting. Our audit included consideration of internal control over
financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the company's internal control over financial
reporting. Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used, significant estimates made by management and evaluating the
overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.

In our opinion, these consolidated financial statements referred to above
present fairly, in all material aspects, the consolidated financial position of
the Company as of December 31, 2008, and the consolidated results of its
operations and cash flows for the year ended December 31, 2008 and for the
period from the date of inception on August 6, 2007 to December 31, 2007 and
2008, in conformity with accounting principles generally accepted in the United
States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company does not have the
necessary working capital to service its debt and for its planned activity,
which raises substantial doubt about its ability to continue as a going concern.
Management's plans in regard to these matters are described in Note 6 to the
financial statements. These financial statements do not include any adjustments
that might result from the outcome of this uncertainty.

/s/Madsen & Associates CPA's, Inc.
Madsen & Associates CPA's, Inc.
March 30, 2009
Salt Lake City, Utah

F-14

HST GLOBAL, INC.
AND SUBSIDIARY
(Formerly NT Holding Corp.)
(a Development Stage Company)
CONSOLIDATED BALANCE SHEETS
December 31, 2008 and 2007

ASSETS

Cash and cash equivalents $ 776
Property, plant and equipment, net of
accumulated depreciation of $483 2,433
------------

TOTAL ASSETS $ 3,210
============

LIABILITIES AND STOCKHOLDERS' EQUITY (Deficiency)

CURRENT LIABILITIES:
Accounts payable and accrued expenses $ 50,865
Deposits - Shareholder 250,000
Advances from Shareholder 2,010
Note Payable - Related Party 100,000
------------

Total Current Liabilities 402,875

STOCKHOLDERS' EQUITY (DEFICIENCY):
Preferred stock; 5,000,000 shares authorized;
..001 par value; 1,000,000 shares issued and
none outstanding
Common stock, $.001 par value; 100,000,000 24,887
shares authorized;
24,886,053 shares issued and outstanding
Additional paid-in capital 1,190,646
Deficit accumulated during the development stage (1,615,198)

Total Stockholders' Equity (Deficiency) (399,665)
------------

TOTAL LIABILITIES AND STOCKHOLDERS'
EQUITY/(DEFICIENCY) $ 3,210
============

F-15

HST GLOBAL, INC.
AND SUBSIDIARY
(Formerly NT Holding Corp.)
(a Development Stage Company)
CONSOLIDATED STATEMENT OF OPERATIONS
Year ended December 31, 2008,
Date of Inception to December 31, 2007,
and Date of Inception to December 31, 2008

From Date From Date
of Inception of Inception
Twelve Months (August 6, 2007) (August 6, 2007)
Ended to to
December 31, December 31, December 31,
2008 2007 2008
--------------- ----------------- -----------------
REVENUES $ - $ - $ -

OPERATING EXPENSES:
Salaries 72,646 30,000 102,646
Consulting 805,327 30,000 835,327
General and
administrative
expenses $ 635,360 2,737 $ 638,097
--------------- ----------------- -----------------

TOTAL OPERATING EXPENSES 1,513,333 62,737 1,576,070
--------------- ----------------- -----------------

NET (LOSS) $ (1,513,333) $ (62,737) $ 1,576,070)
=============== ================= =================

NET INCOME (LOSS) PER SHARE:
BASIC AND DILUTED -
COMMON $ (0.06) $ (0.00)
=============== =================

WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC AND DILUTED -
COMMON 24,386,770 24,030,353
=============== =================

The accompanying notes are an integral part of these financial statements.

F-16

HST GLOBAL, INC.
AND SUBSIDIARY
(Formerly NT Holding Corp.)
(a Development Stage Company)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Year ended December 31, 2008

Common Stock
------------------------- Accum- Net
100,000,000 shares ulated Stock-
authorized Other holders'
Preferred Stock ------------------------- Additional Compre- Equity
--------------- Shares Par Value Paid-In Accumulated hensive (Defic-
Shares Amount Issued stated $.001 Capital (Deficit) (Loss) iency)
------ ------- ---------- ------------- ----------- ------------- --------- ------------
Balance - October 2,
2007 (inception) 0 $ - 0 $ - $ - $ - $ - $ -

Issuance of common
stock for cash - October
2, 2007 1,500 $ 1,500 $ 1,500

Net (Loss) $ (62,737) $ (62,737)

Balance - December
31, 2007 1,500 $ 1,500 $ (62,737) $ (61,237)

Recapitalization -
reverse acquisition 24,030,353 $ 22,533 $ (39,128) $ (16,595)

Issuance of common
stock for cash
at $1.25 per share,
August 2008 839,200 $ 839 $ 1,048,161 $ 1,049,000

Issuance of common
stock for services
valued at $9.50 per
share, August 2008 15,000 $ 15 $ 142,485 $ 142,500

Net (loss) for period $ (1,513,333) $(1,513,333)

Balances - December
31, 2008 24,886,053 $ 24,887 $ 1,190,646 $ (1,615,198) $ (399,665)
========== ============= =========== ============= ============

The accompanying notes are an integral part of these financial statements.

F-17

HST GLOBAL, INC.
AND SUBSIDIARY
(Formerly NT Holding Corp.)
(a Development Stage Company)
CONSOLIDATED STATEMENT OF CASH FLOWS
Year ended December 31, 2008,
Date of Inception to December 31, 2007,
and Date of Inception to December 31, 2008

From Date From Date
of Inception of Inception
(August 6, (August 6,
Year Ended 2007) to 2007) to
December 31, December 31, December 31,
2008 2007 2008
-------------- -------------- --------------
CASH FLOWS FROM
OPERATING ACTIVITIES:
Net income (loss) $ (1,513,333) $ (62,737) $ (1,576,070)
Adjustments to reconcile net
loss to net cash used
in operating activities:
Depreciation and amortization 484 - 484
Common stock issued
for services 142,500 - 142,500
Changes in operating-assets
and liabilities,
net of acquisitions:
Note payable 100,000 - 100,000
Accounts payable and
accrued expenses (11,357) 62,222 50,865
-------------- -------------- --------------

Net Cash used in
Operating Activities (1,281,706) (515) (1,282,221)

CASH FLOWS FROM
INVESTING ACTIVITIES:
Purchase of equipment (2,917) - (2,917)
-------------- -------------- --------------

Net Cash used in
Investing Activities (2,917) - (2,917)

CASH FLOWS FROM
FINANCING ACTIVITIES:
Proceeds from sale
of common stock 1,049,000 1,500 1,050,500
Deposits from shareholder 250,000 - 250,000
Advances from shareholder 2,010 - 2,010
Effect of merger adjustment (16,596) - (16,596)
-------------- -------------- --------------

Net cash provided by
financing activities 1,284,414 1,500 1,285,914

Net Increase (decrease)
in cash (209) 985 776

CASH AT BEGINNING OF PERIOD 985 - -
-------------- -------------- --------------

CASH AT END OF PERIOD $ 776 $ 985 $ 776
============== ============== ==============

The accompanying notes are an integral part of these financial statements.

F-18

HST GLOBAL, INC.
AND SUBSIDIARY
(Formerly NT Holding Corp.)
(a Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES

The Company was incorporated on April 11, 1984 under the laws of the State of
Delaware under the name of NT Holding Corporation. The Company has made several
acquisitions and disposals of various business entities and activities. On May
9, 2008, the Company entered into a Merger and share exchange agreement with
Health Source Technologies, Inc. This business acquisition has been accounted
for as a reverse merger or recapitalization of Health Source Technologies, Inc.
At the time of the merger NT Holding Corporation had disposed of its assets and
liabilities and had minimal operations and was considered a development stage
company. Immediately after the acquisition the Company changed its name to HST
Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of
the State of Nevada on August 6, 2007. The Company is currently headquartered in
Hampton, Virginia.

HST Global, Inc. is an integrated Health and Wellness company that is developing
and/or acquiring a network of Wellness Centers worldwide with the primary focus
on homeopathic and alternative treatments of late stage cancer. In addition, the
Company intends to acquire innovative products for the treatment of late stage
cancer. The Company primarily focuses on homeopathic and alternative product
candidates that are undergoing or have already completed significant clinical
testing for the treatment of late stage cancer.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

CASH AND CASH EQUIVALENTS

The company considers all highly liquid instruments purchased with maturity of
three months or less to be cash equivalents.

REVENUE RECOGNITION

The company considers revenue to be recognized at the time the service is
performed.

USE OF ESTIMATES

The preparation of the Company's financial statements required management to
make estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. Actual results could differ from these
estimates.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company's short-term financial instruments consist of cash and cash
equivalents and accounts payable. The carrying amounts of these financial
instruments approximate fair value because of their short-term maturities.
Financial instruments that potentially subject the Company to a concentration of
credit risk consist principally of cash. During the year the Company did not
maintain cash deposits at

F-19

financial institution in excess of the $250,000 limit covered by the Federal
Deposit InsuranceCorporation. The Company does not hold or issue financial
instruments for trading purposes nor does it hold or issue interest rate or
leverage derivative financial instruments.

EARNINGS PER SHARE

Basic Earnings per Share ("EPS") is computed by dividing net income available to
common stockholders by the weighted average number of common stock shares
outstanding during the year. Diluted EPS is computed by dividing net income
available to common stockholders by the weighted-average number of common stock
shares outstanding during the year plus potential dilutive instruments such as
stock options and warrants. The effect of stock options on diluted EPS is
determined through the application of the treasury exercises are hypothetically
used to repurchase the Company's common stock at the average market price during
the period. Loss per share is unchanged on a diluted basis since the assumed
exercise of common stock equivalents would have an anti-dilutive effect.

INCOME TAXES

The Company uses the asset and liability method of accounting for income taxes
as required by SFAS No. 109 "Accounting for Income Taxes". SFAS 109 requires the
recognition of deferred tax assets and liabilities for the expected future tax
consequences of temporary differences between the carrying amounts and the tax
basis of certain assets and liabilities. Deferred income tax assets and
liabilities are computed annually for the difference between the financial
statement and tax bases of assets and liabilities that will result in taxable or
deductible amounts in the future, based on enacted tax laws and rates applicable
to the periods in which the differences are expected to affect taxable income.
Valuation allowances are established when necessary to reduce deferred tax
assets to the amount expected to be realized. Income tax expense is the tax
payable or refundable for the period, plus or minus the change during the period
in deferred tax assets and liabilities.

Deferred income taxes may arise from temporary differences resulting from income
and expense items reported for financial accounting and tax purposes in
different periods. Deferred taxes are classified as current or non-current,
depending on the classification of the assets and liabilities to which they
relate. Deferred taxes arising from temporary differences that are not related
to an asset or liability are classified as current or non-current depending on
the periods in which the temporary differences are expected to reverse. The
Company had no significant deferred tax items arise during any of the period
presented.

CONCENTRATION OF CREDIT RISK

The Company does not have any concentration of related financial credit risk.

RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not expect that the adoption of other recent accounting
pronouncements will have a material impact to its financial statements.

NOTE 4 - REVERSE MERGER, ACQUISITION AND BUSINESS DISPOSAL

On May 9, 2008, the Company entered into a merger and share exchange agreement
with NT Holding Corp. NT Holding Corp was incorporated on April 11, 1984 under
the laws of the State of Delaware. NT Holding Corp since its inception has been
involved in various business operations including mining and the development of
mineral properties. At the time of the merger and share exchange agreement, NT

F-20

Holding had disposed of its operation assets and previous operations and was
considered a development stage company.

This business acquisition has been accounted for as a reverse merger
(recapitalization) with Health Source Technologies, Inc. deemed to be the
accounting acquirer and NT Holding Corp deemed to be the legal acquirer.
Accordingly, the historical financial information statements presented herein
are those of Health Source Technologies, Inc. The accumulated deficit of the
accounting acquirer has been carried forward after the acquisition as well as
its assets and liabilities. Operations prior to the business combination are
those of the acquirer. In conjunction with this business combination, the Board
of Directors approved a 25 for 1 reverse split of the Company's common stock.
The stock splits have been applied retroactively in the financial statements as
if the split had occurred at the inception of the company.

NOTE 5 - STOCKHOLDERS EQUITY

The Company completed a business combination with Health Source Technologies
Inc. on May 9, 2008 (see Note 4). In conjunction with this acquisition the Board
of Directors approved a 25 for 1 reverse split of the Company's common stock.
Prior to the acquisition the Company had 30,039,203 shares of common stock
outstanding. The issuance of the 66,000,000 new shares of common stock to
facilitate the business combination gave the company a total of 96,039,203
shares outstanding immediately before the stock split. After the stock split
there were 4,041,568 shares outstanding. In addition, the post-acquisition
equity structure was to reflect a 95% ownership by the shareholders of Health
Source Technologies, Inc. In order to facilitate this structure, an additional
99,744,800 pre-split shares were issued and delivered to HST shareholders once
sufficient authorized capital was available. On December 31, 2008, 3,989,792
post split shares were issued. On December 31, 2008, 3,989,792 post split shares
were issued to Ron Howell, an officer and shareholder of the Company and Eric
Clemons, a shareholder of the Company to complete the terms of the acquisition
agreement. These shares have been retroactively reported in the financial
statements as being issued in conjunction with the acquisition that occurred on
May 5, 2008.

As part of the consideration for this business combination there were also
1,000,000 shares of preferred stock issued which where convertible into 16.2
(post split) shares of the company's common stock. These preferred shares were
converted into 16,200,000 shares of common stock.

The Company has received $1,049,000 from various persons and companies as
deposits that were being held by the company in the anticipation of fulfilling a
common stock subscription agreement. On August 20, 2008 the Company issued
839,200 shares of its common stock at a purchase price of $1.25 per share. Also,
on August 20, 2008 the company issued 15,000 shares of common stock in exchange
for legal services rendered to the company. The shares were valued at $9.50 per
share which was the trading price of the shares on the date the shares were
issued.

On October 28, 2008, the company received $250,000 from an investor for working
capital. This investor has agreed to receive 125,000 shares, at a price of $1.25
per share. This transaction has been reported as Deposits from stockholders on
the Company's Financial Statements

F-21

NOTE 6 - FINANCIAL CONDITION AND GOING CONCERN

The Company's financial statements have been presented on the basis that it will
continue as a going concern, which contemplates the realization of assets and
the satisfaction of liabilities in the normal course of business. The Company
incurred a net loss from continuing operations of $1,513,333 for the year ended
December 31, 2008 and has an accumulated deficit of $1,615,198 at December 31,
2008. These factors raise substantial doubt as to its ability to obtain debt
and/or equity financing and achieve profitable operations.

There are no assurances that HSTC will be able to either (1) achieve a level of
revenues adequate to generate sufficient cash flow from operations; or (2)
obtain additional financing through either private placement, public offerings
and/or bank financing necessary to support its working capital requirements. To
the extent that funds generated from operations and any private placements,
public offerings and/or bank financing are insufficient, the Company will have
to raise additional working capital. No assurance can be given that additional
financing will be available, or if available, will be on terms acceptable to
HSTC. If adequate working capital is not available HSTC may be required to
curtail its operations.

NOTE 7 - RELATED PARTY TRANSACTIONS

EXECUTIVE OFFICES

The Company's executive offices are located at 150 Research Dr., Hampton VA.
These offices are leased by The Health Network, Inc. ("THN"), of which Ron
Howell is President. THN allows the Company to use the office space without a
formal sublease or rental agreement.

The Company currently pays The Health Network, Inc. $15,000 per month as a
general operating fee, which covers use of the office space, use of certain
equipment, and various other services. The company paid a total $109,000 to The
Health Network during 2008.

CONSULTING AGREEMENTS

The Company has entered into a consulting agreement with Mr. Howell, President
of the Company, whereby the Company agreed to pay Mr. Howell $10,000 per month
for consulting services thru December 31, 2008. Mr. Howell received $120,000
during 2008. The consulting agreement may be terminated at will by the Company.
The Company intends to continue to engage Mr. Howell as a consultant until his
consulting services are no longer required.

The Company has entered into a consulting agreement with Mr. Clemons, a
shareholder of the Company, whereby the Company agreed to pay Mr. Clemons
$10,000 per month for consulting services thru December 31, 2008. Mr. Clemons
received $120,000 during 2008. The consulting agreement may be terminated at
will by the Company. The Company intends to continue to engage Mr. Clemons as a
consultant until his consulting services are no longer required.

F-22

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURES

None.

ITEM 9A. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures
------------------------------------------------

Our management, including our Principal Executive and Principal Financial
Officer, evaluated the effectiveness of the design and operation of our
disclosure controls and procedures (as defined in Securities Exchange Act Rules
13a-15(e) and 15d-15(e)) as of December 31, 2008. Our disclosure controls and
procedures are designed to ensure that information required to be disclosed by
the issuer in the reports that it files or submits under the Act (15 U.S.C. 78a
et seq.) is recorded, processed, summarized, and reported, within the time
periods specified in the Commission's rules and forms. Disclosure controls and
procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by an issuer in the reports
that it files or submits under the Act is accumulated and communicated to the
issuer's management, including its principal executive and principal financial
officers, or persons performing similar functions, as appropriate to allow
timely decisions regarding required disclosure. Based on this evaluation, our
Chief Executive and Principal Financial Officer concluded that our disclosure
controls and procedures were not effective as of December 31, 2008.

(b) Management's Report on Internal Control over Financial Reporting
----------------------------------------------------------------

Our management is responsible for establishing and maintaining adequate internal
control over financial reporting as defined in Rules 13a-15(f) and 15d-a5(f)
under the Exchange Act. Our internal control over financial reporting is
designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in
accordance with U.S. GAAP. Our internal control over financial reporting
includes those policies and procedures that: (i) pertain to the maintenance of
records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of our assets; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial
statements in accordance with GAAP, and that our receipts and expenditures are
being made only in accordance with authorizations of our management and
directors; and (iii) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use of disposition of our assets that
could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting
may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.

Under the supervision of our Chief Executive Officer and Chief Financial
Officer, our management assessed the effectiveness of our internal control over
financial reporting as of December 31, 2008. In making this assessment,
management used the criteria set forth in Internal Control-Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on this assessment, our management has concluded that our internal control
over financial reporting was ineffective as of December 31, 2008 and there are
material weaknesses in our internal control over financial reporting. A
material weakness is a deficiency, or a combination of control deficiencies, in
internal control over financial reporting such that there is a reasonable
possibility that a material

Page 23

misstatement of our annual or interim financial statements will not be prevented
or detected on a timely basis.

The material weaknesses relate to the limited number of persons responsible for
the recording and reporting of financial information, the lack of separation of
financial reporting duties, and the limited size of our management team in
general. We are in the process evaluating methods of improving our internal
control over financial reporting, including the possible addition of financial
reporting staff and the increased separation of financial reporting
responsibility, and intend to implement such steps as are necessary and possible
to correct these material weaknesses.

This annual report does not include an attestation report of our registered
public accounting firm regarding internal control over financial reporting.
Management's report was not subject to attestation by our registered public
accounting firm pursuant to temporary rules of the SEC that permit us to provide
only management's report in this Annual Report on Form 10-K. Our registered
public accounting firm will not be required to opine on internal controls until
fiscal 2010.

There were no changes in our internal control over financial reporting during
the quarter ended December 31, 2008, that have materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

DIRECTOR AND EXECUTIVE OFFICER SUMMARY

The following table sets forth the names, ages, and principal offices and
positions of our current directors, executive officers, and persons we consider
to be significant employees. The Board of Directors elects our executive
officers annually. Our directors serve one-year terms or until their successors
are elected, qualified and accept their positions. The executive officers serve
terms of one year or until their death, resignation or removal by the Board of
Directors. There are no family relationships or understandings between any of
the directors and executive officers. In addition, there was no arrangement or
understanding between any executive officer and any other person pursuant to
which any person was selected as an executive officer.

NAME OF DIRECTOR OR OFFICER AGE POSITION
Ronald R. Howell 61 Chief Executive Officer and
Chairman of the Board of Directors
Wesley D. Tate 46 Chief Financial Officer
Dr. James Forsythe 69 Director

Page 24

EXECUTIVE OFFICER AND DIRECTOR BIOS

Ronald R. Howell, Chief Executive Officer and Chairman: Mr. Howell has over 30
- -------------------------------------------------------
years of diversified leadership experience. He has distinguished himself in
various businesses and held executive positions in various industries including
real estate, distribution, national and international sales, wholesale and
retail marketing, financial service. Mr. Howell serves as the CEO and President
of The Health Network, Inc. and has served in that capacity for over 5 years.
The Health Network, Inc. is a direct sales and marketing company in the
nutraceutical industry.

Holding a Bachelor's Degree in Management from the University of Maryland and an
MBA from the Sellinger School of Business and Management at Loyola College, Mr.
Howell has also taught as an Adjunct Professor at Loyola College in Baltimore,
Maryland. Ron also served his country as a United States Marine.

Wesley D. Tate, Chief Financial Officer: Prior to joining the Company Mr. Tate
- ----------------------------------------
served as Executive Vice President and Chief Operating Officer for InnerLight
Inc. in Provo Utah for over five years. Before that, he was Assistant Chief
Financial Officer for Beverly Sassoon and Co. in Boca Raton, Florida. Wes has
spent almost 15 years in the Direct Sales Industry working with a number of
different companies. He also has experience outside the direct sales industry,
having worked with a number of fortune 500 companies.

Mr. Tate received his Bachelor of Science degree from the University of
Tennessee, Knoxville, with majors in finance and psychology and his Masters of
Business Administration from the University of Tennessee, Knoxville, with
concentrations in finance and management. Wes served his country in the United
States Army.

Dr. James Forsythe, Director: Dr. Forsythe is both a Medical Doctor and a
- -----------------------------
Homeopathic Physician with over 40 years of experience. Dr. Forsythe has been a
clinical oncologist for 34 years and has done many pre-clinical and clinical
studies. He is the current Owner and Medical Director of the Cancer screening
and Treatment center of Nevada and The Century Wellness Clinic. Dr. Forsythe is
Board certified in Internal Medicine, Medical Oncology and Utilization Review
and Quality Assurance.

Dr. Forsythe received his Bachelor of Science in Biochemistry-Physiology from
the University of California, Berkeley and his Doctorate of Medicine from the
University of California, San Francisco. Dr. Forsythe is an Associate Professor
of Medicine at the University of Nevada, Reno Medical School. Dr. Forsythe
spent 26 years in the United States Army Medical Corps, retiring as a Full
Colonel.

LEGAL AND DISCIPLINARY HISTORY

No officer, director or control person of the Company has been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending
criminal proceeding (excluding traffic violations and other minor
offenses);

2. The entry of an order, judgment, or decree, not subsequently reversed,
suspended or vacated, by a court of competent jurisdiction that permanently
or temporarily enjoined, barred, suspended or otherwise limited such
person's involvement in any type of business, securities, commodities, or
banking activities;

3. A finding or judgment by a court of competent jurisdiction (in a civil
action), the Securities and Exchange Commission, the Commodity Futures
Trading Commission, or a state securities

Page 25

regulator of a violation of federal or state securities or commodities law,
which finding or judgment has not been reversed, suspended, or vacated; or

4. The entry of an order by a self-regulatory organization that permanently or
temporarily barred, suspended or otherwise limited such person's
involvement in any type of business or securities activities.

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act")
requires our directors and officers, and persons who own more than ten percent
of the Common Stock to file reports of ownership and changes in ownership with
the Securities and Exchange Commission ("SEC") and the American Stock Exchange.
SEC regulations require reporting persons to furnish us with copies of all
Section 16(a) forms they file.

Based solely on our review of the copies of the Forms 3, 4 and 5 and amendments
thereto furnished to us by the persons required to make such filings during
fiscal 2008 and our own records, we believe that Mr. Howell, Mr. Tate, Mr.
Clemons, and Dr. Forsythe each failed to file timely a Form 3 to report initial
beneficial ownership.

CORPORATE GOVERNANCE.

We have not adopted a code of ethics do date. We are in the process of
evaluating the standards of conduct necessary for the deterrence of malfeasance
and the promotion of ethical conduct and accountability, and will determine
whether a code of ethics is necessary based on our evaluation.

The Company does not have a standing Nominating Committee. There have been no
changes to the procedures whereby security holders may recommend nominees to the
registrant's board of directors.

The Company is not a "listed issuer" as defined by Rule 10A-3, and does not have
a standing Audit Committee. We do not have a financial expert serving on our
board of directors.

ITEM 11. EXECUTIVE COMPENSATION

COMPENSATION DISCUSSION AND ANALYSIS

Objectives and Philosophy of our Executive Compensation Program
- ---------------------------------------------------------------

We do not have a standing compensation committee. Our board of directors as a
whole makes the decisions as to employee benefit programs and officer and
employee compensation. The primary objectives of our executive compensation
programs are to:

- - attract, retain and motivate skilled and knowledgeable individuals;
- - ensure that compensation is aligned with our corporate strategies and
business objectives;
- - promote the achievement of key strategic and financial performance measures
by linking short-term and long-term cash and equity incentives to the
achievement of measurable corporate and individual performance goals; and
- - align executives' incentives with the creation of stockholder value.

Page 26

To achieve these objectives, our board of directors evaluates our executive
compensation program with the objective of setting compensation at levels they
believe will allow us to attract and retain qualified executives. In addition,
a portion of each executive's overall compensation is tied to key strategic,
financial and operational goals set by our board of directors. We also
generally provide a portion of our executive compensation in the form of options
that vest over time, which we believe helps us retain our executives and align
their interests with those of our stockholders by allowing the executives to
participate in our longer term success as reflected in asset growth and stock
price appreciation.

Named Executive Officers
- ------------------------

The following table identifies our principal executive officer, our principal
financial officer and our most highly paid executive officers, who, for purposes
of this Compensation Disclosure and Analysis only, are referred to herein as the
"named executive officers."

Name Corporate Office
----------- --------------------------------
Ron Howell Chief Executive Officer
Wesley Tate Chief Financial Officer
Alan Lew Former Sole Officer and Director

Components of our Executive Compensation Program
- ------------------------------------------------

At this time, neither of our Named Executive Officers receives compensation for
their services to the Company. Compensation will be negotiated in the near
future and may be contingent on the availability of financing. The primary
elements of our executive compensation program will be base salaries and option
grant incentive awards, although the board of directors has the authority to
award cash bonuses, benefits and other forms of compensation as it sees fit.

The Company has entered into a consulting agreement with Mr. Howell whereby the
Company agreed to pay Mr. Howell $10,000 per month for consulting services thru
December 31, 2008. The consulting agreement may be terminated at will by the
Company. The Company intends to continue to engage Mr. Howell as a consultant
until his consulting services are no longer required.

We do not have any formal or informal policy or target for allocating
compensation between short-term and long-term compensation, between cash and
non-cash compensation or among the different forms of non-cash compensation.
Instead, we have determined subjectively on a case-by-case basis the appropriate
level and mix of the various compensation components. Similarly, we do not rely
on benchmarking against our competitors in making compensation related
decisions.

Base salaries
- -------------

Base salaries will be used to recognize the experience, skills, knowledge and
responsibilities required of our named executive officers. Base salary, and
other components of compensation, may be evaluated by our board of directors for
adjustment based on an assessment of the individual's performance and
compensation trends in our industry.

Equity Awards
- -------------

Our stock option award program will be the primary vehicle for offering
long-term incentives to our executives. To date, we have not issued any equity
awards. We intend our equity awards to executives to generally be made in the
form of warrants. We believe that equity grants in the form of warrants provide

Page 27

our executives with a direct link to our long-term performance, create an
ownership culture, and align the interests of our executives and our
stockholders.

Cash bonuses
- ------------

Our board of directors has the discretion to award cash bonuses based on our
financial performance and individual objectives. The corporate financial
performance measures (revenues and profits) will be given the greatest weight in
this bonus analysis. We have not yet granted any cash bonuses to any named
executive officer nor have we yet developed any specific individual objectives
while we wait to attain revenue and profitability levels sufficient to undertake
any such bonuses.

Benefits and other compensation
- -------------------------------

Our named executive officers are permitted to participate in such health care,
disability insurance, bonus and other employee benefits plans as may be in
effect with the Company from time to time to the extent the executive is
eligible under the terms of those plans. As of the date of this Registration
Statement, with exception to health care, we have not implemented any such
employee benefit plans.

CURRENT COMPENSATION AGREEMENTS

As discussed below, we have not agreed to pay the Named Executive Officers an
annual salary. We will negotiate base salary in the near future. Base salary
may be increased from time to time with the approval of the board of directors.
The following table summarizes the agreed annual salary of each of the named
executive officers:

Summary Annual Salary
- ---------------------

Name Annual Salary
----------- --------------
Ron Howell 0(1)
Wesley Tate 0(2)

(1) Mr. Howell has agreed to defer receiving an annual salary. He has received
$10,000 per month thru December 31, 2008 from the Company pursuant to a
consulting agreement. See "Relationships and Related Transactions," below.
(2) Mr. Tate has agreed to defer receiving an annual salary.

Agreed Compensation
- -------------------

Ron Howell, Chief Executive Officer:

Mr. Howell currently does not receive compensation for his services as Chief
Executive Officer. He has agreed to defer compensation until the Company
obtains sufficient financing. The Board of Directors will determine what level
of compensation is appropriate to offer Mr. Howell in the near future.

Wesley Tate, Chief Financial Officer:

Mr. Tate currently does not receive compensation for his services as Chief
Financial Officer. He has agreed to defer compensation until the Company
obtains sufficient financing. The Board of Directors will determine what level
of compensation is appropriate to offer Mr. Tate in the near future.

Page 28

SUMMARY COMPENSATION TABLE

The following table sets forth the total compensation paid to, or accrued by,
the Named Executive Officers and other employees earning over $100,000 per year
during the fiscal year ended December 31, 2008. No restricted stock awards,
long-term incentive plan payout or other types of compensation, other than the
compensation identified in the chart below and its accompanying notes, were paid
to these executive officers during that fiscal year. Similar information for
the fiscal year ended December 31, 2006 is not included as the Company was
dormant for that period.

ANNUAL OTHER COMPEN- LONG TERM
NAMED COMPEN- ANNUAL ANNUAL SATION COMPEN-
EXECUTIVE SATION COMPENSATION COMPEN- RESTRICTED SATION LTIP
OFFICER YEAR SALARY ($) BONUS ($) SATION STOCK OPTIONS PAYOUTS ALL OTHER
- ------------- ---- ---------- ------------- ---------- ---------- --------- ------- ---------
Ron Howell(1) 2008 0 0 120,000(4) 0 0 0 0
Wes Tate(2) 2008 0 0 0 0 0 0 0
Alan Lew(3) 2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0

1. Mr. Howell joined the Company on May 8, 2008.
2. Mr. Tate joined the Company on May 8, 2008.
3. Mr. Lew was the Company's sole officer and director in the fiscal year ended
December 31, 2007. He resigned in May, 2008 pursuant to the acquisition
agreement between the Company and Health Source Technologies, Inc.
4. Mr. Howell receives $10,000 per month from Health Source Technologies, Inc.,
the Company's operating subsidiary, pursuant to a consulting agreement. Mr.
Howell has been president of Health Source Technologies since inception in 2007.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END TABLE

The following table sets forth information regarding the outstanding warrants
held by our named officers as of December 31, 2008.

OPTION AWARDS
------------------------
EQUITY INCENTIVE
NUMBER OF NUMBER OF PLAN AWARDS:
SECURITIES SECURITIES NUMBER OF
UNDERLYING UNDERLYING SECURITIES
UNEXERCISED UNEXERCISED UNDERLYING OPTION
OPTIONS OPTIONS UNEXERCISED EXERCISE OPTION
(#) EXER- (#) UNEXER- UNEARNED PRICE EXPIRATION
NAME CISABLE CISABLE OPTIONS ($) DATE
- ----------- ----------- ----------- ---------------- --------- ----------
Ron Howell - - - - -
Wesley Tate - - - - -

Page 29

GRANTS OF PLAN-BASED AWARDS TABLE FOR FISCAL YEAR 2008

The Company currently does not participate in any equity award plan. During
fiscal 2008, we did not grant any equity awards under any equity award plan.

OPTION EXERCISES FOR FISCAL 2008

During fiscal 2008, none of the named executive officers exercised options.

NONQUALIFIED DEFERRED COMPENSATION

To date, we currently offer no defined contribution or other plan that provides
for the deferral of compensation on a basis that is not tax-qualified to any of
our employees, including the named executive officers.

COMPENSATION OF DIRECTORS

We intend to use a combination of cash and equity-based compensation to attract
and retain candidates to serve on our board of directors. We intend to
compensate directors who are also our employees for their service on our board
of directors. Therefore, Mr. Howell will receive compensation for his service
on our board of directors, which compensation has not yet been determined.

We have agreed to pay Dr. Forsythe $1,500 per month for his services to the
Board. He was paid $4,500 for July, August and October, and had accrued $4,500
in unpaid compensation as of December 31, 2008. We also intend to issue Dr.
Forsythe 25,000 shares plus 1,000 shares per month of service to the Board, but
have not issued any shares to date. We have not provided any other compensation
to any member of our Board of Directors for the fiscal year ended December 31,
2008.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

We do not currently have a standing Compensation Committee. Our entire board of
directors participated in deliberations concerning executive officer
compensation.

COMPENSATION COMMITTEE REPORT

The board of directors has reviewed and discussed the Compensation Discussion
and Analysis required by Item 402(b) of Regulation S-K with management and,
based on such review and discussions, the board of directors has recommended
that this Compensation Discussion and Analysis be included in this Registration
Statement on Form 10.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table shows the beneficial ownership of our common stock as of
March 27, 2009. The table shows the amount of shares owned by:

(1) each person known to us who owns beneficially more than five percent of
the outstanding shares of any class of the Company's stock, based on the number
of shares outstanding as of March 27, 2009;
(2) each of the Company's Directors and Executive Officers; and
(3) all of its Directors and Executive Officers as a group.

Page 30

AMOUNT OF PERCENT OF
SHARES SHARES
IDENTITY OF BENEFICIALLY BENEFICIALLY
PERSON OR GROUP OWNED OWNED(1,2) CLASS
- ----------------------- ------------ ------------- ------
Ronald R. Howell 10,843,9962 43.57% Common
Chief Executive Officer
and Chairman

Wesley D. Tate 0 0% Common
Chief Financial Officer

Eric Clemons 7,874,696 31.64% Common
150 Research Dr.
Hampton, VA 23666

James Forsythe 0 0% Common
150 Research Dr.
Hampton, VA 23666

All Directors and 10,843,996 43.57% Common
Officers as a Group

(1) The percentage of shares owned is based on 24,886,053 shares of common stock
outstanding as of December 31, 2008. Where the beneficially owned shares of any
individual or group in the following table includes any options, warrants, or
other rights to purchase shares, the percentage of shares owned includes such
shares as if the right to purchase had been duly exercised.

(2) Includes 9,907,696 held personally, and 936,300 held by The Health Network,
Inc., of which he is President.

(3) BENEFICIAL OWNERSHIP OF SECURITIES: Pursuant to Rule 13d-3 under the
Securities Exchange Act of 1934, involving the determination of beneficial
owners of securities, a beneficial owner of securities is person who directly or
indirectly, through any contract, arrangement, understanding, relationship or
otherwise has, or shares, voting power and/or investment power with respect to
the securities, and any person who has the right to acquire beneficial ownership
of the security within sixty days through means including the exercise of any
option, warrant or conversion of a security.

ITEM 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

EXECUTIVE OFFICES

The Company currently pays The Health Network, Inc. $15,000 per month as a
general operating fee, which covers use of the office space, use of certain
equipment, and various other services.

Page 31

CONSULTING AGREEMENTS

The Company has entered into a consulting agreement with Mr. Clemons whereby the
Company agreed to pay Mr. Clemons $10,000 per month for consulting services thru
December 31, 2008. The consulting agreement may be terminated at will by the
Company. The Company intends to continue to engage Mr. Clemons as a consultant
until his consulting services are no longer required.

DIRECTOR INDEPENDENCE

The Company is not listed on any national exchange, or quoted on any
inter-dealer quotation service, that imposes independence requirements on any
committee of the Company's directors, such as an audit, nominating or
compensation committee. The company's Board of Directors consists of Ron
Howell, who is not independent, and Dr. James Forsythe, who is independent.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The following is a summary of the fees paid to Madsen & Associates, the
Company's independent public accounting firm, during the fiscal years ended
December 31, 2008 and 2007.

2008 2007
------- -------
Audit fees $38,410 $28,220
Audit-related fees - -
Tax fees - -
All other fees - -
TOTAL $38,410 $28,220

AUDIT COMMITTEE PRE-APPROVAL OF SERVICES OF PRINCIPAL ACCOUNTANTS

We do not currently have an audit committee appointed by the Board of Directors
and the full Board of Directors did not vote on whether any non-audit services
impacted our auditor's independence. We currently do not have any policy for
approval of audit and permitted non-audit services by our independent auditor.
We plan to appoint an audit committee by our Board of Directors and adopt
procedures for approval of audit and non-audit services.

Page 32

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

FINANCIAL STATEMENTS AND SCHEDULES.

The following consolidated financial statements of HST Global, Inc. and
Subsidiaries are included herein by reference to the pages listed in "Item 8.
Financial Statements and Supplementary Data":

Report of Independent Registered Public Accounting Firm

Consolidated Balance Sheets as of December 31, 2008 and 2007

Consolidated Statements of Operations for the years ended December 31,
2008, and 2007

Consolidated Statements of Changes in Shareholders' Interest for the
years ended December 31, 2008 and 2007

Consolidated Statements of Cash Flows for the years ended December 31,
2008 and 2007

Notes to Consolidated Financial Statements

EXHIBITS

The following Exhibits are included herein:

31.1 Certification of the Principal Executive pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

31.2 Certification of the Principal Financial Officer pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

32.1 Certification by the Principal Executive Officer of HST Global, Inc.
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).

32.2 Certification by the Principal Financial Officer of HST Global, Inc.
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).

Page 33

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

HST GLOBAL, INC.
(the registrant)

By: \s\ Ron Howell
--------------
Ron Howell
Chief Executive Officer

Date: March 31, 2009

Page 34